et al, Homocysteine as a risk factor for vascular disease
10.1038/s41392-023-01570-w [DOI] [PMC free article] [PubMed] [Google Scholar] Chen Z, Wang W, Abdul Razak SR, Han T, Ahmad NH, Li X (2023b) Ferroptosis as a potential target for cancer therapy
The active compound responsible turned out to be a small peptide
Therapeutic interventions aimed at modulating lipid availability, such as ACAT inhibitors, PPAR antagonists, or scavenger-receptor blockade, can reduce the supply of anti-ferroptotic lipid mediators and promote oxidative lipid stress within tumor cells
JAK/STAT3 activation also relates to the MDS-related TOD
The batch-specific CoA for CJC-1295 + Ipamorelin (without DAC) shows an HPLC purity of 99% or higher, identity confirmation via mass spectrometry, the batch number and the net peptide content in milligrams per vial